Skip to content

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery

A Phase Ⅲ, Randomized, Double-Blind, Placebo- and Active-controlled Study of YZJ-4729 Tartrate Injection for the Treatment of Moderate to Severe Pain After Abdominal Surgery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06890533
Enrollment
560
Registered
2025-03-24
Start date
2025-05-14
Completion date
2026-09-01
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

The primary objective is to evaluate the analgesic efficacy and safety of IV YZJ-4729 Tartrate Injection in patients with acute postoperative pain following abdominal surgery.

Interventions

DRUGExperimental: YZJ-4729

Loading dose + demand dose

Loading dose + demand dose

Loading dose + demand dose

Sponsors

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Be able to understand the study purpose and cooperate with the study procedures of this trial, voluntarily provide written informed consent 2. Body mass index (BMI) ≥18 kg/m2 and ≤28 kg/m2. 3. ASA I - II 4. Experiences a pain intensity rating of moderate to severe acute pain following abdominal surgery, with a pain intensity score of ≥4 on a Numeric Rating Scale (NRS) within 4 hours post-surgery

Exclusion criteria

1. Allergy to opioids and other medications that may be used during the trial. 2. Nervous system disorders (e.g. epilepsy) 3. Psychiatric disorders (e.g. depression) 4. History of difficult airways 5. Random blood glucose ≥11.1 mmol/L 6. Uncontrolled blood pressure \[e.g., hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg),or hypotension(systolic blood pressure \<90 mmHg)\] 7. Abnormal pulse oxygen saturation (SpO2 \<90 %) 8. Abnormal liver function or renal function 9. Used agents that could affect the analgesic response 10. Used agents that could affect drug metabolism 11. Has previously participated in another YZJ-4729 clinical study

Design outcomes

Primary

MeasureTime frameDescription
the Sum of Pain Intensity Differences Over 24 Hours at rest24 hoursPain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NRS), with higher numbers indicating a higher pain intensity, administered over 24 hours.

Secondary

MeasureTime frameDescription
The Time to first using rescue analgesics24 hours
The proportion of subjects using rescue analgesics24 hours
The number of times for rescue analgesics using24 hours
The cumulative dose used of rescue analgesics24 hours
the resting Sum of Pain Intensity Differences Over 6、12、18、12-24 Hours24 hours
the active Sum of Pain Intensity Differences Over 6、12、18、24、12-24 Hours24 hours
Participant satisfaction scores for analgesia treatment24 hoursParticipants recalled the postoperative analgesia effect and rated their satisfaction on a scale of 1 to 5, with 1 representing dissatisfied and 5 representing very satisfied.
Investigator satisfaction scores for analgesia treatment24 hoursPostoperative analgesia was evaluated by investigators. The scale ranges from 1 to 5, with 1 being dissatisfied and 5 being very satisfied.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 30, 2026